MDRNA, a Bothell, WA-based developer of RNA interference drugs, said yesterday it has eliminated 23 jobs, leaving it with a staff of 55. Most of the cuts were from its nasal drug delivery program, which was the main concentration of the company for most of its history when it was named Nastech Pharmaceutical. Most employees losing their jobs were given notice Aug. 4 and will leave no later than Aug. 31, the company said. The cuts affect three executives from the company’s nasal delivery business—president Gordon Brandt, chief scientific officer of Delivery Henry Constantino, and chief business officer Timothy Duffy.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
